T cell costimulatory molecules in anti-viral immunity: Potential role in immunotherapeutic vaccines

Canadian Journal of Infectious Diseases

Volumn 14, Issue 4, 2003, Pages 221-229

  Watts, Tania H ^a   Bertram, Edward M ^a   Bukczynski, Jacob ^a   Wen, Tao ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Immunity; Lymphocytes; Therapeutic vaccines; Vaccination; Viral infection

Indexed keywords

T LYMPHOCYTE RECEPTOR; VIRUS VACCINE;

ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; CHRONIC DISEASE; DRUG EFFICACY; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VIRUS IMMUNITY; VIRUS INFECTION;

EID: 0142022922     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/2003/214034     Document Type: Review

References (72)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
2. Kelsall BL, Biron CA, Sharma O, Kaye PM. Dendritic cells at the host-pathogen interface. Nature Immunology 2002;3:699-702.
3. Janeway CA Jr, Medzhitov R. Innate immune recognition. Ann Rev Immunol 2002;20:197-216.
4. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970;169:1042-9.
5. Schwartz RH. Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065-8.
6. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Ann Rev Immunol 1996;14:233-58.
7. Watts TH, DeBenedette MA. T cell costimulatory molecules other than CD28. Curr Op Immunol 1999;11:286-93.
8. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nature Rev Immunol 2002;2:116-26.
9. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001;104:487-501.
10. Green JM, Noel PJ, Sperling AI, et al. Absence of B7-dependent responses in CD28-deficient mice. Immunity 1994;1:501-8.
11. Shahinian A, Pfeffer K, Lee KP, et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993;261:609-12.
12. Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999;397:263-5.
13. Dong C, Juedes AE, Temann U-A, et al. ICOS co-stimulatory receptor is essential for T cell activation and function. Nature 2001;409:97-101.
14. McAdam AJ, Greenwald RJ, Levin MA, et al. ICOS is critical for CD40-mediated antibody class switching. Nature 2001;409:102-5.
15. Tafuri A, Shahinian A, Bladt F, et al. ICOS is essential for effective T-helper-cell responses. Nature 2001;409:105-9.
16. Greenwald RJ, McAdam AJ, Van der Woude D, Satoskar AR, Sharpe AH. Cutting edge: Inducible costimulator protein regulates both Th1 and Th2 responses to cutaneous leishmaniasis. J Immunol 2002;168:991-5.
17. Bertram EM, Tafuri A, Shahinian A, et al. Role of ICOS versus-CD28 in anti-viral immunity. Eur J Immunol 2002;32:3376-85.
18. Kopf M, Coyle AJ, Schmitz N, et al. Inducible costimulator protein (ICOS) controls T helper cell subset polarization after virus and parasite infection. J Exp Med 2000;192:53-61.
19. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997;7:445-50.
20. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-7.
21. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270:985-8.
22. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-I gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-51.
23. Egen JG, Kuhns MS, Allison JP. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nature Immunol 2002;3:611-8.
24. Gravestein LA, Borst J. Tumor necrosis factor receptor family members in the immune system. Sem Immunol 1998;10:423-34.
25. Kwon B, Youn BS, Kwon BS. Functions of newly identified members of the tumour necrosis factor receptor/ligand superfamily in lymphocytes. Curr Op Immunol 1999;11:340-5.
26. Arch RH, Gedrich RW, Thompson CB. Tumor necrosis factor receptor-associated factors (TRAFs) - Family of adapter proteins that regulates life and death. Genes Dev 1998;12:2821-30.
27. Benedict CA, Norris PS, Ware CF. To kill or be killed: Viral evasion of apoptosis. Nature Immunol 2002;3:1013-8.
28. Benedict CA, Butrovich KD, Lurain NS, et al. Cutting edge: A novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. J Immunol 1999;162:6967-70.
29. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Ann Rev Immunol 1998;16:111-35.
30. Vinay DS, Kwon BS. Role of 4-1BB in immune responses. Sem Immunol 1998;10:481-9.
31. DeBenedette MA, Shahinian A, Mak TW, Watts TH. Costimulation of CD28-T lymphocytes by 4-1BB ligand. J Immunol 1997;158:551-9.
32. Weinberg AD, Vella AT, Croft M. OX-40: Life beyond the effector T cell stage. Sem Immunol 1998;10:471-80.
33. Chen AI, McAdam AJ, Buhlmann JE, et al. Ox40-ligand has a critical costimulatory role in dendritic cell: T cell interactions. Immunity 1999;11;689-98.
34. Pippig SD, Pena-Rossi C, Long J, et al. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40). J Immunol 1999;163:6520-9.
35. Kopf M, Ruedl C, Schmitz N, et al. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection. Immunity 1999;11:699-708.
36. Murata K, Ishii N, Takano H, et al. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J Exp Med 2000;191:365-74.
37. DeBenedette MA, Wen T, Bachmann MF, et al. Analysis of 4-1BB ligand-deficient mice and of mice lacking both 4-1BB ligand and CD28 reveals a role for 4-1BB ligand in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J Immunol 1999;163:4833-41.
38. Bertram EM, Lau P, Watts TH. Temporal segregation of CD28 versus 4-1BBL-mediated costimulation: 4-1BBL Influences T cell numbers late in the primary response and regulates the size of the memory response following influenza infection. J Immunol 2002;168:3777-85.
39. Tan JT, Whitmire JK, Murali-Krishna K, et al. 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination. J Immunol 2000;164:2320-5.
40. Cannons JL, Lau P, Ghumman B, et al. 4-1BBL induces cell division, sustains survival and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol 2001;167:1313-24.
41. Azuma M, Phillips JH, Lanier LL. CD28-T lymphocytes. Antigenic and functional properties. J Immunol 1993;150:1147-59.
42. Effros RB, Boucher N, Porter V, et al. Decline in CD28+ T cells in centenarians and in long-term T cell cultures: A possible cause for both in vivo and in vitro immunosenescence. Exp Gerontol 1994;29:601-9.
43. Bukczynski J, Wen T, Watts TH. Costimulation of human CD28-T cells by 4-1BB ligand. Eur J Immunol 2003;33:446-54.
44. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nature Med 2002;8:379-85.
45. Scott-Algara D, Buseyne F, Blanche S, et al. Frequency and phenotyping of human immunodeficiency virus (HIV)-specific CD8+ T cells in HIV-infected children, using major histocompatibility complex class I peptide tetramers. J Infect Dis 2001;183:1565-73.
46. Weekes MP, Carmichael AJ, Wills MR, Mynard K, Sissons JG. Human CD28-CD8+ T cells contain greatly expanded functional virus-specific memory CTL clones. J Immunol 1999;162:7569-77.
47. Mugnaini EN, Spurkland A, Egeland T, Sannes M, Brinchmann JE. Demonstration of identical expanded clones within both CD8+CD28+ and CD8+CD28- T cell subsets in HIV type 1-infected individuals. Eur J Immunol 1998;28:1738-42.
48. Trimble LA, Shankar P, Patterson M, Daily JP, Lieberman J. Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3zeta and CD28, key signaling molecules for T cell activation. J Virol 2000;74:7320-30.
49. Sze DM, Giesajtis G, Brown RD, et al. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood 2001;98:2817-27.
50. Halstead ES, Mueller YM, Altman JD, Katsikis PD. In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses. Nat Immunol 2002;3:536-41.
51. Miller RE, Jones J, Le T, et al. 4-1BB-Specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol 2002;169:1792-800.
52. Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997;186:47-55.
53. Altman JD, Moss PAH, Goulder PJR, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-6.
54. McHeyzer-Williams MG, Altman JD, Davis MM. Tracking antigen-specific helper T cell responses. Curr Opin Immunol 1996;8:278-84.
55. Appay V, Rowland-Jones SL. The assessment of antigen-specific CD8+ T cells through the combination of MHC class I tetramer and intracellular staining. J Immunol Methods 2002;268:9-19.
56. Busch, DH, Pilip, IM, Vijh, S, Pamer, EG. Coordinate regulation of complex T cell populations responding to bacterial infection. Immunity 1998;8:353-62.
57. Flynn KJ, Riberdy JM, Christensen JP, Altman JD, Doherty PC. In vivo proliferation of naive and memory influenza-specific CD8(+) T cells. Proc Natl Acad Sci U S A 1999;96:8597-602.
58. Murali-Krishna K, Altman JD, Suresh M, et al. Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection. Immunity 1998;8:177-87.
59. Sprent J, Surh CD. T cell memory. Ann Rev Immunol 2002;20:551-79.
60. Busch DH, Pilip I, Pamer EG. Evolution of a complex T cell receptor repertoire during primary and recall bacterial infection. J Exp Med 1998;188:61-70.
61. Mercado R, Vijh S, Allen SE, Kerksiek K, Pilip IM, Pamer EG. Early programming of T cell populations responding to bacterial infection. J Immunol 2000;165:6833-9.
62. Wong P, Pamer EG. Cutting edge: Antigen-independent CD8 T cell proliferation. J Immunol 2001;166:5864-8.
63. van Stipdonk MJ, Lemmens EE, Schoenberger SP. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2001;2:423-9.
64. Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: Initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2001;2:415-22.
65. Badovinac VP, Porter BB, Harty JT. Programmed contraction of CD8(+) T cells after infection. Nat Immunol 2002;3:619-26.
66. Guinn BA, DeBenedette MA, Watts TH, Berinstein NL. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999;162:5003-10.
67. Pisetsky DS, St Clair EW. Progress in the treatment of rheumatoid arthritis. JAMA 2001;286:2787-90.
68. Babiuk LA, Tikoo SK. Adenoviruses as vectors for delivering vaccines to mucosal surfaces. J Biotechnol 2000;83:105-13.
69. Hardy GA, Imami N, Gotch FM. Improving HIV-specific immune responses in HIV-infected patients. J HIV Ther 2002;7:40-5.
70. Stephenson JR. Genetically modified viruses: Vaccines by design. Curr Pharm Biotechnol 2001;2:47-76.
71. Levine BL, Bernstein WB, Aronson NE, et al. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med 2002;8:47-53.
72. Takeda K, Akira S. Roles of Toll-like receptors in innate immune responses. Genes Cells 2001;6:733-42.